adalimumab biosimilar
/ Mabscale
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 29, 2023
Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
(clinicaltrials.gov)
- P3 | N=494 | Recruiting | Sponsor: Mabscale, LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Immunology • Psoriasis
August 22, 2023
Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
(clinicaltrials.gov)
- P3 | N=494 | Not yet recruiting | Sponsor: Mabscale, LLC
New P3 trial • Dermatology • Immunology • Psoriasis
1 to 2
Of
2
Go to page
1